XML 41 R26.htm IDEA: XBRL DOCUMENT v3.24.2

Other Gains and Losses, and Litigation	6 Months Ended
	Jun. 30, 2024
Analysis of income and expense [abstract]
Other Gains and Losses, and Litigation	B.17. OTHER GAINS AND LOSSES, AND LITIGATION For the first half of 2024, Other gains and losses, and litigation is a charge of €442 million, mainly comprising a provision recognized in respect of the litigation related to Plavix (clopidogrel) in the US state of Hawaii (see note B.14.). That compares with a charge of €73 million in the first half of 2023, which comprised costs related to the settlement of a dispute with shareholders of Bioverativ.

X

- References

No definition available.

+ Details

Name:	ifrs-full_AnalysisOfIncomeAndExpenseAbstract
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure of other gains and losses, and litigation.

+ References

No definition available.

+ Details

Name:	sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock
Namespace Prefix:	sny_
Data Type:	dtr-types1:textBlockItemType
Balance Type:	na
Period Type:	duration